PD-1 refractory melanoma: BRAF MEK vs IPI/NIVO

Описание к видео PD-1 refractory melanoma: BRAF MEK vs IPI/NIVO

[Oncoinfo – Istantanee di Oncologia: seguici su http://oncoinfo.it] After patients get single agent anti-PD1, what is better if they progress to give them anti-PD1 anti-CTLA-4 ipilimumab or if the patients’ tumor is BRAF V600 to give them targeted therapy? We asked Jeffrey Sosman (Northwestern University Department of Medicine, Chicago, Illinois, US) about his position after the Great Debate about the issue at Melanoma Bridge 2024.

Комментарии

Информация по комментариям в разработке